Silence Therapeutics’ lead siRNA asset for the rare blood cancer polycythemia vera has been earning analyst raves in a tight race to challenge Takeda in a potential $2 billion market. hubs.li/Q04Bz2-_0

AbbVie’s next-gen dual-targeting therapy elicited higher rates of remission than its IL-23 inhibitor Skyrizi in a Phase 2a trial of Crohn’s disease, leading analysts to wonder if the blockbuster can be outdone. hubs.li/Q04ByYw50

Roche is offering $400 million upfront and over $15 billion in biobucks to team up with Hansoh Pharmaceutical in hopes of developing a portfolio of new antibody-drug conjugates using the latter’s in-house tech. hubs.li/Q04ByxqF0

The new policy signals an escalation by the Chinese government on biopharma deals but is unlikely to have a major impact given that the vast majority of foreign interest in Chinese biotech comes in the form of licensing agreements. hubs.li/Q04By53p0

Novartis will continue to study Fabhalta in other indications, with late-stage studies in two rare diseases—atypical haemolytic uraemic syndrome and generalized myasthenia gravis—expected to read out later this year and next year, respectively. hubs.li/Q04By4RG0

Disc Medicine’s bitopertin—rejected by the FDA in February—significantly reduced levels of a key disease biomarker and significantly increased the time patients with erythropoietic protoporphyria were able to spend in the sun and artificial light. hubs.li/Q04Bx_br0

In the wake of a successful IPO and strong stock growth throughout the year, Veradermics now has late-stage data to support a regulatory package for its hair loss pill. hubs.li/Q04BxD4T0

High-quality cytokines for organoid growth, differentiation, and expansion hubs.li/Q04BxCQc0

At the European Society of Medical Oncology meeting in Madrid this weekend, analysts will be watching for detailed data on Merck and Moderna’s personalized cancer vaccine, Summit and Akeso’s PD-1xVEGF bispecific therapy, and many antibody-drug conjugates. hubs.li/Q04BxCGT0

While GLP-1 medicines are now synonymous with weight loss, one expert thinks amylin would have been the go-to target if biopharma had focused on the blockbuster indication 10 years ago. A new wave of therapies explores this potentially gentler mechanism. hubs.li/Q04BxB760

As trispecifics, cell engagers and other complex formats multiply, drug developers are seeking discovery and engineering partners to help navigate an expanding universe of molecular possibilities. hubs.li/Q04BxzBQ0

Estuary Biotherapeutics is seeking to address the root cause of autosomal dominant polycystic kidney disease with two gene therapy programs based on science from Yale. hubs.li/Q04BpCWr0

City Therapeutics will join a slew of biotechs that have entered the public markets this year, with a $200 million raise that landed above expectations. hubs.li/Q04BpCnr0

Inconsistent reporting at a Pennsylvania site affected microbiological analyses of components and drug products that analytical testing service provider Eurofins ran for customers. hubs.li/Q04BnFlz0

The sixth cycle of OrbiMed’s Asia Partners fund included one with more than $1 billion earmarked for life science companies based on the Eastern continent. hubs.li/Q04BnBRc0

After years of quiet maturation, new approach methodologies and emerging clinical success for cell therapies are fueling parallel momentum for induced pluripotent stem cells. hubs.li/Q04Bnzlf0

AstraZeneca will tap AI-focused insitro to find new targets for metabolic dysfunction-associated steatohepatitis and cardiomyopathies, following the Phase 3 failure of its Ionis-partnered Wainua in transthyretin-mediated amyloid cardiomyopathy. hubs.li/Q04BgSMy0

Less than a month after announcing that it would shutter its German manufacturing facility and slash about 650 jobs there, GSK is cutting more than 1,200 roles in Belgium as part of its $2.5 billion global restructuring. hubs.li/Q04BgHzl0

Following several recent initiatives, the FDA’s newest rare disease framework sets out to standardize the agency’s approach to scientific evidence and bring rare disease therapies to patients faster. hubs.li/Q04BgGpT0

A new biotech co-founded by Paul Stoffels has formed to take on the CAR T cell assets of Galapagos almost a year after the company—now known as Lakefront Biotherapeutics—abandoned them. hubs.li/Q04BgFyP0